Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man

Bile acids (BAs) traversing the enterohepatic circulation exert several important metabolic effects. Their hepatic synthesis, controlled by the enzyme cholesterol 7α‐hydroxylase (CYP7A1), has a unique diurnal variation in man. Here we provide evidence that the transintestinal flux of BAs regulates serum levels of intestinal fibroblast growth factor 19 (FGF19) that in turn modulate BA production in human liver. Basal FGF19 levels varied by 10‐fold in normal subjects, and were reduced following treatment with a BA‐binding resin and increased upon feeding the BA chenodeoxycholic acid. Serum FGF19 levels exhibited a pronounced diurnal rhythm with peaks occurring 90–120 min after the postprandial rise in serum BAs. The FGF19 peaks in turn preceded the declining phase of BA synthesis. The diurnal rhythm of serum FGF19 was abolished upon fasting. We conclude that, in humans, circulating FGF19 has a diurnal rhythm controlled by the transintestinal BA flux, and that FGF19 modulates hepatic BA synthesis. Through its systemic effects, circulating FGF19 may also mediate other known BA‐dependent effects on lipid and carbohydrate metabolism.

[1]  D. Mangelsdorf,et al.  LXRS and FXR: the yin and yang of cholesterol and fat metabolism. , 2006, Annual review of physiology.

[2]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[3]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Angelin,et al.  Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. , 2005, Gastroenterology.

[5]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[6]  B. Staels,et al.  The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[7]  I. Schulman,et al.  Regulation of Complement C3 Expression by the Bile Acid Receptor FXR* , 2005, Journal of Biological Chemistry.

[8]  G. Salen,et al.  Bile acid biosynthesis , 1974, The American Journal of Digestive Diseases.

[9]  R. Myers,et al.  Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)? , 2004, Endocrinology.

[10]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[11]  B. Angelin,et al.  Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood Published, JLR Papers in Press, January 16, 2003. DOI 10.1194/jlr.D200043-JLR200 , 2003, Journal of Lipid Research.

[12]  B. Angelin,et al.  Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. , 2003, Journal of lipid research.

[13]  D. Russell,et al.  Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. , 2002, Developmental cell.

[14]  M. Karin,et al.  Redundant pathways for negative feedback regulation of bile acid production. , 2002, Developmental cell.

[15]  D. French,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .

[16]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[17]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[18]  C. Deng,et al.  Elevated Cholesterol Metabolism and Bile Acid Synthesis in Mice Lacking Membrane Tyrosine Kinase Receptor FGFR4* , 2000, The Journal of Biological Chemistry.

[19]  A. Goddard,et al.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. , 1999, Cytokine.

[20]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[21]  N. Itoh,et al.  Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. , 1999, Biochimica et biophysica acta.

[22]  S. Hughes,et al.  Differential Expression of the Fibroblast Growth Factor Receptor (FGFR) Multigene Family in Normal Human Adult Tissues , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  J. Chiang,et al.  Identification and characterization of a putative bile acid-responsive element in cholesterol 7 alpha-hydroxylase gene promoter. , 1994, The Journal of biological chemistry.

[24]  K. Einarsson,et al.  Bile acid synthesis in humans: regulation of hepatic microsomal cholesterol 7 alpha-hydroxylase activity. , 1989, Gastroenterology.

[25]  K. Einarsson,et al.  Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. , 1982, The Journal of clinical investigation.

[26]  K. Einarsson,et al.  Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. , 1978, Journal of lipid research.